RU2013136350A - Фармацевтическая композиция, содержащая опиоидный агонист и секвестрированный антагонист - Google Patents
Фармацевтическая композиция, содержащая опиоидный агонист и секвестрированный антагонист Download PDFInfo
- Publication number
- RU2013136350A RU2013136350A RU2013136350/15A RU2013136350A RU2013136350A RU 2013136350 A RU2013136350 A RU 2013136350A RU 2013136350/15 A RU2013136350/15 A RU 2013136350/15A RU 2013136350 A RU2013136350 A RU 2013136350A RU 2013136350 A RU2013136350 A RU 2013136350A
- Authority
- RU
- Russia
- Prior art keywords
- layer
- agonist
- covering
- antagonist
- naltrexone hcl
- Prior art date
Links
- 239000003402 opiate agonist Substances 0.000 title claims abstract 22
- 239000005557 antagonist Substances 0.000 title claims abstract 21
- 239000008194 pharmaceutical composition Substances 0.000 title claims 3
- 229960003086 naltrexone Drugs 0.000 claims abstract 29
- DQCKKXVULJGBQN-XFWGSAIBSA-N naltrexone Chemical compound N1([C@@H]2CC3=CC=C(C=4O[C@@H]5[C@](C3=4)([C@]2(CCC5=O)O)CC1)O)CC1CC1 DQCKKXVULJGBQN-XFWGSAIBSA-N 0.000 claims abstract 29
- 239000000203 mixture Substances 0.000 claims abstract 24
- 239000000556 agonist Substances 0.000 claims abstract 21
- 230000014759 maintenance of location Effects 0.000 claims abstract 20
- 229920000642 polymer Polymers 0.000 claims abstract 20
- 238000013270 controlled release Methods 0.000 claims abstract 7
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims abstract 7
- BRUQQQPBMZOVGD-XFKAJCMBSA-N Oxycodone Chemical group O=C([C@@H]1O2)CC[C@@]3(O)[C@H]4CC5=CC=C(OC)C2=C5[C@@]13CCN4C BRUQQQPBMZOVGD-XFKAJCMBSA-N 0.000 claims abstract 3
- 229960002085 oxycodone Drugs 0.000 claims abstract 3
- ZFSXKSSWYSZPGQ-UHFFFAOYSA-N (2-hydroxycyclopentyl)azanium;chloride Chemical compound Cl.NC1CCCC1O ZFSXKSSWYSZPGQ-UHFFFAOYSA-N 0.000 claims 6
- 229960000858 naltrexone hydrochloride Drugs 0.000 claims 6
- BQNSLJQRJAJITR-UHFFFAOYSA-N 1,1,2-trichloro-1,2-difluoroethane Chemical compound FC(Cl)C(F)(Cl)Cl BQNSLJQRJAJITR-UHFFFAOYSA-N 0.000 claims 4
- 239000002552 dosage form Substances 0.000 claims 4
- 238000000034 method Methods 0.000 claims 4
- 229960003617 oxycodone hydrochloride Drugs 0.000 claims 4
- 230000036470 plasma concentration Effects 0.000 claims 3
- 208000000094 Chronic Pain Diseases 0.000 claims 2
- 208000002193 Pain Diseases 0.000 claims 2
- 239000008363 phosphate buffer Substances 0.000 claims 1
- 239000010410 layer Substances 0.000 abstract 16
- 239000012792 core layer Substances 0.000 abstract 1
- 239000008298 dragée Substances 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/5073—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings
- A61K9/5078—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings with drug-free core
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/485—Morphinan derivatives, e.g. morphine, codeine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Landscapes
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Epidemiology (AREA)
- Emergency Medicine (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pain & Pain Management (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201161438882P | 2011-02-02 | 2011-02-02 | |
| US61/438,882 | 2011-02-02 | ||
| PCT/IB2012/050348 WO2012104752A1 (en) | 2011-02-02 | 2012-01-25 | Pharmaceutical composition comprising opioid agonist and sequestered antagonist |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| RU2013136350A true RU2013136350A (ru) | 2015-03-27 |
Family
ID=45607315
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| RU2013136350/15A RU2013136350A (ru) | 2011-02-02 | 2012-01-25 | Фармацевтическая композиция, содержащая опиоидный агонист и секвестрированный антагонист |
Country Status (14)
| Country | Link |
|---|---|
| US (1) | US20140141090A1 (https=) |
| EP (1) | EP2670400A1 (https=) |
| JP (3) | JP2014504630A (https=) |
| KR (4) | KR20190014577A (https=) |
| CN (1) | CN103415285A (https=) |
| AU (3) | AU2012213056A1 (https=) |
| BR (1) | BR112013019431A2 (https=) |
| CA (1) | CA2824835A1 (https=) |
| IL (1) | IL227770A0 (https=) |
| MX (1) | MX2013008225A (https=) |
| RU (1) | RU2013136350A (https=) |
| SG (1) | SG191872A1 (https=) |
| WO (1) | WO2012104752A1 (https=) |
| ZA (1) | ZA201305108B (https=) |
Families Citing this family (20)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2092936B1 (en) | 2000-02-08 | 2013-03-20 | Euro-Celtique S.A. | Tamper-resistant oral opioid agonist formulations |
| US20110104214A1 (en) | 2004-04-15 | 2011-05-05 | Purdue Pharma L.P. | Once-a-day oxycodone formulations |
| MX391660B (es) | 2010-03-24 | 2025-03-21 | Jazz Pharmaceuticals Inc | Formas de dosis de liberacion controlada para substancias de farmaco de alta dosis, solubles en agua e higroscopicas |
| US10398662B1 (en) | 2015-02-18 | 2019-09-03 | Jazz Pharma Ireland Limited | GHB formulation and method for its manufacture |
| US11602513B1 (en) | 2016-07-22 | 2023-03-14 | Flamel Ireland Limited | Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics |
| US11504347B1 (en) | 2016-07-22 | 2022-11-22 | Flamel Ireland Limited | Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics |
| US11986451B1 (en) | 2016-07-22 | 2024-05-21 | Flamel Ireland Limited | Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics |
| UY37341A (es) | 2016-07-22 | 2017-11-30 | Flamel Ireland Ltd | Formulaciones de gamma-hidroxibutirato de liberación modificada con farmacocinética mejorada |
| US12186296B1 (en) | 2016-07-22 | 2025-01-07 | Flamel Ireland Limited | Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics |
| US12478604B1 (en) | 2016-07-22 | 2025-11-25 | Flamel Ireland Limited | Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics |
| US11602512B1 (en) | 2016-07-22 | 2023-03-14 | Flamel Ireland Limited | Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics |
| US20180263936A1 (en) | 2017-03-17 | 2018-09-20 | Jazz Pharmaceuticals Ireland Limited | Gamma-hydroxybutyrate compositions and their use for the treatment of disorders |
| IL311303B1 (en) * | 2017-10-09 | 2026-01-01 | Rhodes Pharmaceuticals Lp | Medicinal resin components and methods for their production and use |
| BR112021006027A2 (pt) * | 2018-11-19 | 2021-06-29 | Jazz Pharmaceuticals Ireland Limited | formulações de fármaco resistente a álcool |
| CN113473980A (zh) | 2019-03-01 | 2021-10-01 | 弗拉梅尔爱尔兰有限公司 | 在进食状态下具有改善的药代动力学的γ-羟基丁酸酯组合物 |
| TW202139986A (zh) | 2020-02-21 | 2021-11-01 | 愛爾蘭商爵士製藥愛爾蘭有限責任公司 | 治療原發性嗜睡症之方法 |
| US12582622B2 (en) | 2020-10-08 | 2026-03-24 | Jazz Pharmaceuticals Ireland Limited | Sodium oxybate to treat idiopathic hypersomnia |
| KR20230071228A (ko) | 2021-11-16 | 2023-05-23 | 김명진 | 가상공간에 사용자가 마시는 주류를 적용하기 위한 방법 및 장치 |
| US11779557B1 (en) | 2022-02-07 | 2023-10-10 | Flamel Ireland Limited | Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics |
| US11583510B1 (en) | 2022-02-07 | 2023-02-21 | Flamel Ireland Limited | Methods of administering gamma hydroxybutyrate formulations after a high-fat meal |
Family Cites Families (22)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4293539A (en) | 1979-09-12 | 1981-10-06 | Eli Lilly And Company | Controlled release formulations and method of treatment |
| GB9104854D0 (en) | 1991-03-07 | 1991-04-17 | Reckitt & Colmann Prod Ltd | Sustained release compositions |
| US5656295A (en) | 1991-11-27 | 1997-08-12 | Euro-Celtique, S.A. | Controlled release oxycodone compositions |
| US5266331A (en) | 1991-11-27 | 1993-11-30 | Euroceltique, S.A. | Controlled release oxycodone compositions |
| US5585115A (en) | 1995-01-09 | 1996-12-17 | Edward H. Mendell Co., Inc. | Pharmaceutical excipient having improved compressability |
| SE9600070D0 (sv) * | 1996-01-08 | 1996-01-08 | Astra Ab | New oral pharmaceutical dosage forms |
| EP2092936B1 (en) | 2000-02-08 | 2013-03-20 | Euro-Celtique S.A. | Tamper-resistant oral opioid agonist formulations |
| CN2423892Y (zh) * | 2000-04-30 | 2001-03-21 | 尹为民 | 分隔式药物胶囊 |
| CA2446738C (en) | 2001-05-11 | 2012-05-29 | Endo Pharmaceuticals, Inc. | Abuse-resistant opioid dosage form |
| IL160222A0 (en) * | 2001-08-06 | 2004-07-25 | Euro Celtique Sa | Opioid agonist formulations with releasable and sequestered antagonist |
| AR040588A1 (es) | 2002-07-26 | 2005-04-13 | Schering Corp | Formulacion farmaceutica que comprende un inhibidor de la absorcion del colesterol y un inhibidor de una hmg- co a reductasa |
| US20040202717A1 (en) | 2003-04-08 | 2004-10-14 | Mehta Atul M. | Abuse-resistant oral dosage forms and method of use thereof |
| DE10353186A1 (de) | 2003-11-13 | 2005-06-16 | Röhm GmbH & Co. KG | Mehrschichtige Arzneiform, enthaltend eine in Bezug auf die Wirkstoffabgabe modulatorisch wirkende Substanz |
| DE10353196A1 (de) | 2003-11-13 | 2005-06-16 | Röhm GmbH & Co. KG | Mehrschichtige Arzneiform mit einer die Abgabe einer modulatorischen Substanz beeinflussenden Matrix |
| US7201920B2 (en) | 2003-11-26 | 2007-04-10 | Acura Pharmaceuticals, Inc. | Methods and compositions for deterring abuse of opioid containing dosage forms |
| AU2005240137B2 (en) | 2004-05-04 | 2010-04-15 | Innophos, Inc. | Directly compressible tricalcium phosphate |
| SI2719378T1 (sl) | 2006-06-19 | 2016-11-30 | Alpharma Pharmaceuticals Llc | Farmacevtski sestavki |
| US20080233156A1 (en) * | 2006-10-11 | 2008-09-25 | Alpharma, Inc. | Pharmaceutical compositions |
| CA2709905A1 (en) * | 2007-12-17 | 2009-06-25 | Alfred Liang | Abuse-resistant oxycodone composition |
| US8623418B2 (en) * | 2007-12-17 | 2014-01-07 | Alpharma Pharmaceuticals Llc | Pharmaceutical composition |
| CN101461809A (zh) * | 2007-12-18 | 2009-06-24 | 重庆药友制药有限责任公司 | 一种泮托拉唑钠肠溶片及其制备方法 |
| RU2541159C2 (ru) * | 2010-10-26 | 2015-02-10 | АЛФАРМА ФАРМАСЬЮТИКЭЛЗ, ЭлЭлСи | Композиции и способы для смягчения дыхательной недостаточности, вызванной передозировкой опиоидов |
-
2012
- 2012-01-25 BR BR112013019431-6A patent/BR112013019431A2/pt not_active IP Right Cessation
- 2012-01-25 CA CA2824835A patent/CA2824835A1/en not_active Abandoned
- 2012-01-25 CN CN2012800076033A patent/CN103415285A/zh active Pending
- 2012-01-25 KR KR1020197002897A patent/KR20190014577A/ko not_active Ceased
- 2012-01-25 KR KR1020187006298A patent/KR20180027641A/ko not_active Ceased
- 2012-01-25 KR KR1020137023085A patent/KR20130124551A/ko not_active Ceased
- 2012-01-25 JP JP2013552292A patent/JP2014504630A/ja not_active Withdrawn
- 2012-01-25 RU RU2013136350/15A patent/RU2013136350A/ru not_active Application Discontinuation
- 2012-01-25 AU AU2012213056A patent/AU2012213056A1/en not_active Abandoned
- 2012-01-25 MX MX2013008225A patent/MX2013008225A/es unknown
- 2012-01-25 EP EP12704131.7A patent/EP2670400A1/en not_active Withdrawn
- 2012-01-25 KR KR1020167005412A patent/KR20160031038A/ko not_active Ceased
- 2012-01-25 SG SG2013052188A patent/SG191872A1/en unknown
- 2012-01-25 WO PCT/IB2012/050348 patent/WO2012104752A1/en not_active Ceased
- 2012-01-25 US US13/982,890 patent/US20140141090A1/en not_active Abandoned
-
2013
- 2013-07-08 ZA ZA2013/05108A patent/ZA201305108B/en unknown
- 2013-08-01 IL IL227770A patent/IL227770A0/en unknown
-
2016
- 2016-02-04 AU AU2016200708A patent/AU2016200708A1/en not_active Abandoned
- 2016-12-07 JP JP2016237476A patent/JP2017081942A/ja not_active Withdrawn
-
2017
- 2017-07-07 AU AU2017204639A patent/AU2017204639A1/en not_active Abandoned
-
2018
- 2018-03-07 JP JP2018040441A patent/JP2018109059A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| CN103415285A (zh) | 2013-11-27 |
| EP2670400A1 (en) | 2013-12-11 |
| MX2013008225A (es) | 2013-08-12 |
| KR20190014577A (ko) | 2019-02-12 |
| JP2014504630A (ja) | 2014-02-24 |
| JP2017081942A (ja) | 2017-05-18 |
| BR112013019431A2 (pt) | 2020-10-27 |
| AU2017204639A1 (en) | 2017-07-27 |
| SG191872A1 (en) | 2013-08-30 |
| IL227770A0 (en) | 2013-09-30 |
| JP2018109059A (ja) | 2018-07-12 |
| CA2824835A1 (en) | 2012-08-09 |
| KR20180027641A (ko) | 2018-03-14 |
| AU2012213056A1 (en) | 2013-07-25 |
| ZA201305108B (en) | 2014-09-25 |
| KR20130124551A (ko) | 2013-11-14 |
| US20140141090A1 (en) | 2014-05-22 |
| WO2012104752A1 (en) | 2012-08-09 |
| AU2016200708A1 (en) | 2016-02-25 |
| KR20160031038A (ko) | 2016-03-21 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| RU2013136350A (ru) | Фармацевтическая композиция, содержащая опиоидный агонист и секвестрированный антагонист | |
| JP2014504630A5 (https=) | ||
| RU2013117274A (ru) | Композиции и способы для смягчения дыхательной недостаточности, вызванной передозировкой опиоидов | |
| JP2013540807A5 (https=) | ||
| US20240350479A1 (en) | Systems and Methods for Treating an Opioid-Induced Adverse Pharmacodynamic Response | |
| AR079862A1 (es) | Composicion de topiramato con sabor enmascarado, un comprimido desintegrable oralmente que comprende la misma y metodo de preparacion | |
| JP2011137020A5 (https=) | ||
| PH12015502134A1 (en) | Mosapride sustained-release preparation for providing pharmacological and clinical effects with once-a-day administration | |
| RU2011138490A (ru) | Фармацевтические композиции с мгновенным высвобождением, содержащие оксикодон и налоксон | |
| RU2011104146A (ru) | Фармацевтическая композиция, содержащая опиоидный антагонист, для лечения задержки мочи | |
| JP2013537915A5 (https=) | ||
| NZ587202A (en) | Methods for measuring a patient response upon administration of a drug and compositions thereof | |
| WO2007111945A3 (en) | Method for management of diarrhea | |
| HRP20171743T1 (hr) | Sastavi i postupci za savladavanje otpornosti na tramadol | |
| HRP20100373T4 (hr) | Upotreba kombinacije morfina s najmanje jednim opijatnim antagonistom u liječenju ovisnosti o opijatima i u sprječavanju neoralne zloupotrebe opijata kod ovisnika opijatima | |
| JP2017526719A5 (https=) | ||
| JP2013505260A5 (https=) | ||
| RU2012115450A (ru) | Применение антагонистов опиоидных рецепторов при заболеваниях желудочно-кишечного тракта | |
| US20230390281A1 (en) | Opioid for use to reduce and/or drug addiction | |
| RU2017134794A (ru) | Комбинированная лекарственная форма антагониста мю-опиоидного рецептора и опиоидного средства | |
| MX2012006920A (es) | Composicion farmaceutica que contiene telmisartan e hidroclorotiazida. | |
| RU2014125702A (ru) | Фармацевтическая композиция для профилактики или лечения гиперлипидемии | |
| CN109364078A (zh) | 纳洛酮在制备镇痛药物中的应用 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FA92 | Acknowledgement of application withdrawn (lack of supplementary materials submitted) |
Effective date: 20150428 |
|
| FZ9A | Application not withdrawn (correction of the notice of withdrawal) |
Effective date: 20160421 |